LC-MS/MS method for the determination of the prodrug aripiprazole lauroxil and its three metabolites in plasma and its application to in vitro biotransformation and animal pharmacokinetic studies
Swiss Official Gazette of Commerce notice: HR of Canton Zug: No. of SOGC 026 from 07.02.2018/Notice no 4041105/New entries
Change in the Board of Directors
Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder
SEC Filings: Form 6-K: Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act 01/30/18
SEC Filings: Form 424B3: Form of prospectus reflecting facts events constituting substantive change from last form 01/04/18
NDA for Novel Major Depressive Disorder Treatment Submitted to FDA
Briefing.com: Hourly In Play (R) - 20:00 ET
Alkermes falls in 4 out of last 5 days January 31, 2018 16:00 EST
SEC Filings: Form 424B5: Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3 01/29/18

Pages